IQ EQ FUND MANAGEMENT IRELAND Ltd Purchases 215 Shares of Zoetis Inc. (NYSE:ZTS)

IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its position in shares of Zoetis Inc. (NYSE:ZTS) by 2.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 9,036 shares of the company’s stock after purchasing an additional 215 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd’s holdings in Zoetis were worth $1,472,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in shares of Zoetis by 0.3% during the fourth quarter. Vanguard Group Inc. now owns 41,366,877 shares of the company’s stock valued at $6,739,905,000 after buying an additional 120,158 shares during the last quarter. State Street Corp boosted its holdings in Zoetis by 0.5% during the 3rd quarter. State Street Corp now owns 19,779,344 shares of the company’s stock valued at $3,864,488,000 after acquiring an additional 95,856 shares during the period. Geode Capital Management LLC grew its position in Zoetis by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 10,427,760 shares of the company’s stock valued at $2,030,813,000 after acquiring an additional 185,364 shares during the last quarter. Polen Capital Management LLC increased its stake in Zoetis by 17.5% in the fourth quarter. Polen Capital Management LLC now owns 7,483,194 shares of the company’s stock worth $1,219,237,000 after purchasing an additional 1,116,541 shares during the period. Finally, Bank of New York Mellon Corp lifted its position in shares of Zoetis by 8.5% during the fourth quarter. Bank of New York Mellon Corp now owns 5,561,910 shares of the company’s stock worth $906,202,000 after purchasing an additional 433,429 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Zoetis

In other news, Director Willie M. Reed sold 1,210 shares of the business’s stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the sale, the director now owns 11,245 shares in the company, valued at approximately $1,868,244.30. The trade was a 9.71 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Roxanne Lagano sold 326 shares of the stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the transaction, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at $2,757,196.26. The trade was a 1.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,862 shares of company stock valued at $312,254 in the last ninety days. Corporate insiders own 0.16% of the company’s stock.

Zoetis Stock Up 1.4 %

NYSE:ZTS opened at $165.12 on Friday. The company’s 50-day simple moving average is $166.46 and its 200-day simple moving average is $174.87. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.33. The stock has a market capitalization of $73.94 billion, a P/E ratio of 30.19, a P/E/G ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating the consensus estimate of $1.37 by $0.03. The company had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. On average, equities analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be paid a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.21%. Zoetis’s dividend payout ratio (DPR) is 36.56%.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Morgan Stanley reduced their target price on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. Piper Sandler raised their price objective on Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a report on Thursday, February 27th. Leerink Partners initiated coverage on Zoetis in a research report on Monday, December 2nd. They set an “outperform” rating and a $215.00 target price for the company. Stifel Nicolaus dropped their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Finally, Barclays upped their price objective on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research note on Friday, February 14th. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Zoetis has an average rating of “Buy” and an average price target of $215.90.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.